Avelumab (anti-PD-L1), CAS 1537032-82-8

Product Description: Avelumab (anti-PD-L1) is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity[1].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Fujii R, et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget. 2016 Jun 7;7(23):33498-511. /[2]Grenga I, et al. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunology. 2016 May 20;5(5):e83./[3]Vandeveer AJ, et al. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. Cancer Immunol Res. 2016 May;4(5):452-62.

CAS Number: 1537032-82-8

Molecular Weight: N/A

Compound Purity: 96.02

Research Area: Cancer; Inflammation/Immunology

Solubility: 10 mM in DMSO

Target: PD-1/PD-L1

• Artikelnummer: MEXHY-108730A-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-108730A-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK